Advertisement

Zusammenfassung

Als Wirkungsmechanismus des Naftidrofuryl konnte sein Antagonismus an Serotonin 5-HT2-Rezeptoren beschrieben werden (Maloteaux et al. 1986, Verheggen und Schrör 1988, 1993, Bodin und Travo 1990, Hollenberg und Nie 1990). 5-HT2-Rezeptoren sind auf Thrombozyten, der glatten Gefäßmuskulatur und auf zentralnervösen Neuronen lokalisiert (Wiernsperger 1990, Hoyer 1994). Ihre Stimulation führt zu einer Thrombozytenaggregation, einer Vasokonstriktion und einer Myozytenproliferation. Auch wurde eine Erhöhung der Kapillarpermeabilität und in deren Folge die Ausbildung lokaler Mikroödeme beschrieben (Vanhoutte 1987). Während bei intaktem Endothel Serotonin rezeptorvermittelt zu einer Aktivierung der NO-Synthase und damit zur Bildung des vasodilatierenden NO führt, kommt es bei Endothelschäden, wie sie z. B. in Folge eines atherosklerotischen Prozesses beobachtet werden, direkt zu einer Vasokonstriktion.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Admani AK (1978) New approach to treatment of recent stroke. Br Med J 2: 1678–1679PubMedCrossRefGoogle Scholar
  2. Adriaensen H (1974) Essai clinique en double aveugle de Praxilene gélules dans l’insuffisance vasculaire cerebrale. Klin Prüfbericht. Lipha-Arzneimittel GmbH, DeutschlandGoogle Scholar
  3. Agnoli A, Martucci N, Manna V (1985) Quantitative EEG as a tool in neuropharmacological studies. The effect of Naftidrofuryl in C.C.V.D. Curr Ther Res 37: 1–11Google Scholar
  4. Autret A, Lehert P, Mosnier M (1992) Study of naftidrofuryl in cerebral ischaemic accidents. Psych Med 24: 103–114Google Scholar
  5. Bargheon J (1975) Essai en double aveugle du Praxilene en geriatrie. Gaz Med France 82: 4755–4758Google Scholar
  6. Bodin P, Travo P (1990) Effects of Naftidrofuryl on the concentration and proliferation of cultured myocytes evoked by serotonin. J Cardio vasc Pharmacol 16 [Suppl 3]: 25Google Scholar
  7. Bonaventura G (1993) In: Landgraf H, Jung F, Ehrly M (Hrsg) Klinische Mikrozirkulation und Hämorheologie. 10. Jahrestagung der Deutschen Gesellschaft für klinische Mikrozirkulation und Hämorheologie, BerlinGoogle Scholar
  8. Bornstein S, Tastayre R, Mosnier M (1993) Etude double-aveugle de l’efficacité du Naftidrofuryl dans les troubles cognitifs liés à la senescence. Rev Geriatrie 18/6: 355Google Scholar
  9. Bouvier JB, Passeron O, Chupin MP (1974) Psychometric study of Praxilene. J Int Med Res 2: 59–65Google Scholar
  10. Capon A, Lehert P, Opsomer L (1990) Naftidrofuryl in the treatment of subacute stroke. J Cardiovasc Pharmacol [Suppl 3] 16: S62–S66PubMedGoogle Scholar
  11. Cohn B, Wilcox S (1986) Praxilene (Naftidrofuryl) in the treatment of senile dementia. In: Trübestein GG (Hrsg) Konservative Therapie arterieller Durchblutungsstörungen. Thieme, Stuttgart, S 330–333Google Scholar
  12. Cox JR, Shaw AM (1981) Controlled trial of Naftidrofuryl in dementia in old age. J Clin Exp Gerontol 3: 339–343Google Scholar
  13. Cucinotta D, Dall’Asta D, Bernaglia F, Ciotti C, Nicora M, Passeri M (1987) Efficacia e tollerabilità del trattamento a lungo termine con Naftidrofuryl di pazienti affetti da Demenza Senile. Studio controllato versus Placebo. G Clin Med 68: 211–217PubMedGoogle Scholar
  14. Dagani F, Curti D, Zanada F, Marzatico F (1984) Effect of Naftidrofuryl on acetylcholinesterase and other enzyme activities in the brain areas of hypoxic rats. J Cereb Blood Flow Metab 4: 615–624PubMedCrossRefGoogle Scholar
  15. Dartenuc JY, Bellooussof F, Meriaud M, Cavel M, Choussat H (1978) Etude en double-aveugle du Praxilène dans l’insuffisance circulatoire du vieillard. Gériatrie 6: 325–327Google Scholar
  16. Ducarne H (1986) Evaluation of a vasoactive substance, Naftidrofuryl, during the rehabilitation phase after an ischaemic insult. Curr Med Res Opin 10: 158–171CrossRefGoogle Scholar
  17. Felix W, Schneider E, Kloppenburg K (1991) Effect of Naftidrofuryl and ketanserin on 5-HT2-re-ceptors of vascular endothelial cells. Int J Microcirc Clin Exp 10: 253Google Scholar
  18. Fontaine L, Grand M, Szarvasi E, Bayssat M (1969) Etude de l’activité vasodilatatrice du Naftidrofuryl. Bull Chim Thér 1: 39–43Google Scholar
  19. Fouillet X (1979) LS 121: Essai de mutagénicité dans le système Salmonella-Microsomes (Test de Ames). Interner Bericht. Lipha-Arzneimittel GmbH, DeutschlandGoogle Scholar
  20. Fujikura H, Kato H, Nakano S, Kogure KA (1989) A Serotonin S2-antagonist (Naftidrofuryl) exhibited a marked protective effect on ischemic brain damage in the gerbil. Brain Res 494: 387–390PubMedCrossRefGoogle Scholar
  21. Gerin J (1974) Double-blind trial of Naftidrofuryl in the treatment of cerebral arteriosclerosis. Br J Clin Pract 28: 177–178PubMedGoogle Scholar
  22. Globus MY, Wester P, Busto R, Dietrich D (1992) Ischemia-induced extracelluar release of serotonin plays a role in CA1 neuronal cell death in rats. Stroke 23: 1596–1601CrossRefGoogle Scholar
  23. Grossmann WM, Standl A, May U, Van Laak HH, Hirche H (1990) Naftidrofuryl in the treatment of mild senile dementia. A double-blind study. Pharmacopsychiatry 23/6: 265CrossRefGoogle Scholar
  24. Grossmann WM, Standl A, May U, Van Laak HH, Hirche H (1991) Naftidrofuryl in the treatment of mild senile dementia. Pharmacopsychiatry 23: 265–273CrossRefGoogle Scholar
  25. Hollenberg NK, Nie Q (1990) The effect of Naftidrofuryl, a 5-HT2 antagonist, on collateral vascular responses to serotonin and to platelet activation. J Cardiovasc Pharmacol 16 [Suppl 3]:36Google Scholar
  26. Hoyer D, Clark DE, Fozard JR, Harting PR, Martin GR, Mylecharane EJ, Saxena TR, Humpfrey PRA (1994) International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157PubMedGoogle Scholar
  27. Israel L, Dell’Accio E, Hugonot R (1989) Kombinationswirkung von Naftidrofuryl und mentalen Übungen auf Gedächtnisstörungen bei alten Patienten. Psychol Med 21: 1219–1234Google Scholar
  28. Judge TG, Urquhart A (1972) Naftidrofuryl double-blind cross-over study in the elderly. Curr Med Res Opin 1: 166–172PubMedCrossRefGoogle Scholar
  29. Kienbaum P, Braun M, Hohlfeld T, Weber AA, Sarbia M, Schrör K (1995) Antiatherosclerotic effects of oral Naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function. J Cardiovasc Pharmacol 25: 774PubMedCrossRefGoogle Scholar
  30. Kitagawa H, Nakata R, Yano H (1973) Etude du métabolisme de l’oxalate de Naftidrofuryl. Oyo Yakuri 7: 1231Google Scholar
  31. Kobayashi S, Yamaguchi S, Katsube T, Okada K, Kitani M, Murao M, Tsunematsu T (1984) Effects of Naftidrofuryl on the time course of the regional cerebral blood flow in acute ischemic stroke. Drug Res 34: 1580–1583Google Scholar
  32. Krieglstein J, Stierstorfer HJ (1988) Improvement of postischemic rat brain energy metabolism and function by naftidrofuryl. Biochem Pharmacol 37: 2285–2286PubMedCrossRefGoogle Scholar
  33. Kuntzmann F, Gitz AM, Bucher ME (1980) Praxilene in the treatment of cerebral vascular insufficiency in the elderly: double-blind controlled clinical trial. Klin Prüfungsbericht. Lipha-Arzneimittel GmbH, DeutschlandGoogle Scholar
  34. Lamproglou Y, Le Poncin M, Jacques W, Wiernsperger N, Rapin JR (1992) Postischemic breakdown in hippocampal protein synthesis and mnesic deficits in rats: pharmacological improvement by curative naftidrofuryl treatment. Metabol Brain Dis 7: 165–174CrossRefGoogle Scholar
  35. Lanza F, Hemmendinger S, Cazenave J-P (1987) Naftidrofuryl inhibits selectively human platelet activation by serotonin. 5th European Conference on Clinical Haemorheology, Bordeaux, June 29–July 1, 1987Google Scholar
  36. Lefebvre PP, Staecker H, Moonen G, Van de Water TR (1993) Naftidrofuryl affects neurite regeneration by injured adult auditory neurons. Acta Otolaryngol (Stockh) 113: 498–501CrossRefGoogle Scholar
  37. Le Poncin-Lafitte M, Grosdemouge CH, Roy-Billon C, Duterte D, Rapin JR (1982) Wirkung von Naftidrofuryl auf zerebrale Hämodynamik, Metabolismus und Funktion nach einer regressiven Ischämie. Arch Int Pharmacodyn 260: 218–229PubMedGoogle Scholar
  38. Louis JC (1989) Effect of naftidrofuryl on metabolism and survival of cultured neurons. Neurochem Res 14: 1195–1201PubMedCrossRefGoogle Scholar
  39. Maloteaux JM, Haiech J, De Campeneere D, Berta P, Vidal N (1986) Biochemical and physiological evidences for antiserotonergic properties of naftidrofuryl. Arzneimittelforschung/Drug Res 36: 1194–1198Google Scholar
  40. Maury S, Fondarai J, Baudu C, Vaudu V (1993) Etude du Naftidrofuryl versus placébo dans le déficit intellectuel pathologique chez des patients ambulatoires. Rev Geriat 18: 239Google Scholar
  41. Meininger V, Chaineau E, Soudiere B (1994) Effet du naftidrofuryl (LS 129) sur la repuousse axonale. Rev Neurol (Paris) 150: 115–122Google Scholar
  42. Miyake K, Taguchi T, Tanonaka K, Horiguchi T, Takagi N, Takeo S (1992) Beneficial effects of naftidrofuryl oxalate on brain regional energy metabolism after microsphere-induced cerebral embolism. J Pharmacol Exp Ther 260: 1058–1066PubMedGoogle Scholar
  43. Miyake K, Tanonaka K, Nasa Y, Takagi N, Tsuchiya T, Yoshizawa M, Fujioka Y, Takeo S (1993) Effects of naftidrofuryl oxalate on microsphere embolism-induced changes in tricaboxylic acid cycle intermediates of rats. Eur J Pharmacol 235: 75–81PubMedCrossRefGoogle Scholar
  44. Miyake K, Takagi N, Takeo S (1994) Effects of Naftidrofuryl oxalate on microsphere embolism-induced decrease in regional blood flow of rat brain. Br J Pharmacol 112: 226–230PubMedCrossRefGoogle Scholar
  45. Nabeshima T, Ichihara K, Tohyama K, Murase K, Suzuki T, Kameyama T (1991) Involvement of serotonergic neuronal systems in the anti-amnesic action of naftidrofuryl oxalate. Eur J Pharmacol 205: 55–61PubMedCrossRefGoogle Scholar
  46. Nordt FJ, Jack W, Coull BM (1990) Influence of Naftidrofuryl, a serotonergic antagonist, on erythrocyte aggregation. J Cardiovasc Pharmacol 16 [Suppl 3]: 29Google Scholar
  47. Ogawa S, Kameyama T, Nabeshima T (1991) Naftidrofuryl oxalate, nootropic effects on the scopolamine and the basal forebrain lesion-induced amnesia in rats. Pharmacol Biochem Behav 39: 997–1002PubMedCrossRefGoogle Scholar
  48. Orgogozo JM, Lehert P, Mosnier M (1995) Double-blind study of naftidrofuryl on secondary outcome after MCA infarction. (Publikation in Vorbereitung) sowie: Abstract, 4th European Stroke Conference, BourdeauxGoogle Scholar
  49. Oudart N (1990) Naftidrofuryl inhibits contractions to serotonin in intact and de-endothelialized cerebral arteries in vitro. J Cardiovasc Pharmacol 16 [Suppl 3]: 45Google Scholar
  50. Rico AG, Godfrain JC, Burgat-Saaze M, Benard P, Braun JP, Fontaine EL, Belleville M (1974) Contribution à l’étude de métabolisme du naftidrofuryl à l’aide de carbone radio-actif. Thérapie 29: 281–293PubMedGoogle Scholar
  51. Robinson K (1972) A double-blind clinical trial of Naftidrofuryl in cerebral vascular disorders. Med Digest 12: 50–55Google Scholar
  52. Roger M, David E (1987) Gevatran 200 (Naftidrofuryl) et sénescence cérébrale — efficacité et tolérance. Impact — Le Praticien P.P.P. 6–7Google Scholar
  53. Saldmann F, Funel A, Jacquet P (1991) Efficacy of naftidrofuryl in patients with moderate senile dementia. Curr Med Res Opin 12: 379–389PubMedCrossRefGoogle Scholar
  54. Schwabedal PE, Wittkowski W, Bauch J, Pluina M, Berg V, Brügging-Schmitz G, Eickmeyer F, Krocke J (1992) Prophylaxe der Koronarskle-rose durch Naftidrofuryl bei hypertonen Ratten. In: Assmann G, Betz E (Hrsg) Koronare Herzkrankheit. Molekulargenetische Aspekte und zelluläre Mechanismen, Risikoprofile vor und nach invasiven Therapieverfahren. Edition Dino, Vieweg, S 27–34Google Scholar
  55. Steiner TJ, Macwalter R, Sanders E (1995) Naftidrofuryl promotes earlier recovery from acute cerebral infarction: principal results of the PRISTINE study. Eur J Neurol 2 (Abstracts, First Congress of the European Federation of Neurological Societies)Google Scholar
  56. Takahashi S, Meiraku Y (1971) Sur les absorptions, concentrations, excrétions du Naftidrofuryl-Oxalate. Interner Bericht. Lipha-Arzneimittel GmbH, DeutschlandGoogle Scholar
  57. Takeo S, Miyake K, Minematsu R, Tanonaka K, Konishi M (1989) In vitro effect of naftidrofuryl oxalate on cerebral mitochondria impaired by microsphere-induced embolism in rats. J Pharmacol Exp Ther 248: 1207–1214PubMedGoogle Scholar
  58. Taguchi T, Takagi N, Miyake K, Tanonaka K, Okada M, Kajihara H, Takeo S (1994) Effects of naftidrofuryl oxalate on micropshere-induced changes in acetylcholine and amino acid content of rat brain regions. Exp Brain Res 99: 7–16PubMedCrossRefGoogle Scholar
  59. Tatematsu A, Nadai T, Yoshizumi H (1974) Study on drug metabolites by mass spectrometry. Biomed Mass Spectrometry 1: 66–72CrossRefGoogle Scholar
  60. Trouillas (1976) Essai en double aveugle: Praxilène-gélules contre placebo lactose. Klin Prüfungsbericht. Lipha-Arzneimittel GmbH, DeutschlandGoogle Scholar
  61. Vanhoutte PM (1987) Serotonin and the vascular wall. Int J Cardiol 14: 189–203PubMedCrossRefGoogle Scholar
  62. Verheggen R, Schrör K (1988) Hemmung der spasmogenen Wirkung von exogenem und endogenem Serotonin auf isolierte Gefäßpräparate durch Naftidrofuryl. VASA [Suppl 24]: 5–10Google Scholar
  63. Verheggen R, Schrör K (1993) Effect of Naftidrofuryl on platelet-induced vasospasm im vitro. Role of antiserotonergic actions. Arzneimittel-forschung/Drug Res 43: 330Google Scholar
  64. Wiernsperger N (1990) Serotonin 5-HT2 receptors and brain circulation. J Cardiovasc Pharmacol 16: S20–S24PubMedGoogle Scholar
  65. Wyllie MG, Paciorek PM, Waterfall JF (1981) Adenosinetriphosphate conversation by indoramin and other drugs. Biochem Pharmacol 30: 1605–1612PubMedCrossRefGoogle Scholar
  66. Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA (1982) Effect of Nafronyl on lactate and pyruvate in the cerebrospinal fluid of patients with senile dementia. J Am Geriatr Soc 30: 105–108PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • H. Herrschaft

There are no affiliations available

Personalised recommendations